If you have been reading about Reference standard and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
Laboratory characterization of GHK-Cu typically combines separation, spectroscopic, and elemental techniques. Reverse-phase high-performance liquid chromatography is widely used to assess peptide purity, often with ultraviolet detection near the copper-related absorption band or with mass spectrometry for identity confirmation. Because the molecule contains copper, elemental methods such as inductively coupled plasma mass spectrometry or atomic absorption spectroscopy are used to quantify metal content and confirm stoichiometry. No single universal pharmacopeial monograph exists for GHK-Cu. Laboratories therefore validate their own methods, and reported purity values depend on the chosen assay and calibration standards.
Stability of GHK-Cu is influenced by light, oxygen, moisture, pH, and temperature. Solid material is generally kept desiccated and frozen to reduce hydrolysis and oxidation, while aqueous solutions are best prepared fresh or stored cold in aliquots. Repeated freeze-thaw cycles can promote aggregation, precipitation, or peptide degradation. Copper coordination may change under strongly acidic or alkaline conditions, potentially altering the complex's spectroscopic properties. Published long-term stability data for specific matrices, such as cosmetic emulsions or biological buffers, are limited, so shelf-life claims should be treated as formulation-specific rather than universal.
Quality control for GHK-Cu relies on documentation and independent testing rather than a single accepted standard. A certificate of analysis may report peptide purity, copper content, residual solvents, water content, and microbial limits, but the underlying methods and acceptance criteria vary by supplier. Verification can include mass confirmation, amino acid analysis, and comparison with a reference standard when one is available. Open questions include how different copper-binding modes or peptide isomers affect measured activity and whether conventional purity assays capture those differences. Buyers of research-grade material typically need to request raw data rather than rely solely on a summary certificate.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) peptide complex | Peptide chain coordinated to a single metal ion |
| CAS number | 89030-95-5 | Indexed for the peptide-copper complex |
| Molecular formula | C14H22CuN6O4 | Approximate formula for a one-to-one complex |
| Appearance | Blue to violet solid | Color from copper d-d transitions |
| Solubility class | Freely soluble in water | Also dispersible in some polar solvents |
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
The compound was first isolated from human plasma in the 1970s by Loren Pickart, who later described copper-binding activity in liver and other tissues. Early reports focused on its presence in blood and its ability to carry copper between proteins. Commercial and cosmetic use of the term 'copper peptide' has since broadened, and labels rarely distinguish GHK-Cu from other copper-binding fragments. This naming overlap makes literature searching harder, because cosmetic ingredient lists, supplier catalogues and laboratory papers use different vocabularies for the same molecule.
GHK-Cu is the copper-binding complex formed by the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The free peptide is usually written as GHK, and the complex is written as GHK-Cu or Cu-GHK. The sequence was identified in human plasma and later detected in saliva and urine. Its name comes from the single-letter codes of glycine, histidine and lysine. The complex is widely described as a naturally occurring carrier of copper in blood rather than as a free peptide with its own hormonal role.
Copper binds to the peptide through the histidine imidazole nitrogen and the terminal amino group, forming a stable square-planar complex. Binding constants reported for copper(II) with GHK are high, so the peptide competes effectively for copper in solution. The complex absorbs visible light, which gives solutions a blue to violet colour. Whether the metal-free peptide has a distinct biological function of its own is still an open question; some work treats it mainly as a copper delivery vehicle, while other work reports peptide-specific effects.
=== LeukoSite === Springer has played a prominent role in biotechnology. His scientific and entrepreneurial work has contributed to multiple FDA-approved therapies in immunology, oncology, and rare diseases, and he has been an influential early investor and company founder in the life sciences industry. In the early 1990s, Springer founded LeukoSite to develop therapeutics based on leukocyte adhesion and trafficking biology. LeukoSite’s programs advanced or incorporated three agents that ultimately became approved medicines: vedolizumab (Entyvio), a humanized antibody targeting integrin α4β7 for inflammatory bowel disease; bortezomib (Velcade) for multiple myeloma and mantle cell lymphoma; and alemtuzumab (Campath-1/Lemtrada) for B-cell chronic lymphocytic leukemia and multiple sclerosis. Millennium Pharmaceuticals acquired LeukoSite in late 1999 by issuing shares; after the merger, LeukoSite shareholders owned 35% of Millennium stock. LeukoSite’s antibody program targeting integrin α4β7 was the foundation for vedolizumab (Entyvio), approved by the FDA in 2014 for ulcerative colitis and Crohn’s disease. Entyvio has since become a major product in the immunology space: Takeda, which acquired the asset through its purchase of Millennium, reported Entyvio revenue of JPY 914.1 billion, approximately US$6.1 billion, for the fiscal year ended March 31, 2025. More than 350,000 patients have been treated with Entyvio since 2014 in the U.S., based on Symphony claims data (June 2014-Jan 2025). Takeda has described Entyvio as a cornerstone of its portfolio.
=== Other ventures === Around 2013, Newell co-founded and funded Foundry10, an educational research organization. In 2018, Newell donated $20 million to the American artificial intelligence company OpenAI and acted as an informal advisor. In 2022, with Philip Sabes, Newell co-founded the neuroscience company Starfish Neuroscience to develop neural interfaces. In May 2025, Starfish announced that their first chip would be released late that year. Newell is the owner of the marine research organization Inkfish, which owns several ships and submarines. In November 2022, Inkfish purchased the Hadal Exploration System, a private deep-sea exploration platform, from the undersea explorer Victor Vescovo. In August 2025, Newell acquired the privately owned yacht manufacturer Oceanco.
Calcium ions are one type of second messengers and are responsible for many important physiological functions including muscle contraction, fertilization, and neurotransmitter release. The ions are normally bound or stored in intracellular components (such as the endoplasmic reticulum(ER)) and can be released during signal transduction. The enzyme phospholipase C produces diacylglycerol and inositol trisphosphate, which increases calcium ion permeability into the membrane. Active G-protein open up calcium channels to let calcium ions enter the plasma membrane. The other product of phospholipase C, diacylglycerol, activates protein kinase C, which assists in the activation of cAMP (another second messenger).
Sources: en.wikipedia.org
== Clinical relevance == Interference with aminoacylation may be useful as an approach to treating some diseases: cancerous cells may be relatively vulnerable to disturbed aminoacylation compared to healthy cells. The protein synthesis associated with cancer and viral biology is often very dependent on specific tRNA molecules. For instance, for liver cancer charging tRNA-Lys-CUU with lysine sustains liver cancer cell growth and metastasis, whereas healthy cells have a much lower dependence on this tRNA to support cellular physiology. Similarly, hepatitis E virus requires a tRNA landscape that substantially differs from that associated with uninfected cells. Hence, inhibition of aminoacylation of specific tRNA species is considered a promising novel avenue for the rational treatment of a plethora of diseases.
Serpin A12 (OL-64, Vaspin, Visceral adipose-specific serpin, Ser A12) is a glycoprotein that is a class A member of the serine protease inhibitor (serpin) family. In humans, Serpin A12 is encoded by the SERPINA12 gene. First discovered in 2005, Serpin A12 was highly expressed in white adipose tissue of Otsuka Long Evans Tokushima Fatty Rats at the same time that the rats' obesity and insulin plasma levels reached a peak, at around 30 weeks old. Eventually, it was found to be expressed in visceral and subcutaneous adipose tissue of obese humans, leading the protein to be linked with obesity, glucose metabolism, and insulin resistance.
== Characteristics == The genome of C. xerosis is approximately 2.7 million base pairs long with over 2,000 genes encoding proteins and a high G+C content. C. xerosis was found to contain a series of plasmids, one of which confers resistance to common antibiotics such as chloramphenicol, kanamycin, streptomycin, and tetracycline and was named pTP10. This plasmid has since been introduced into Bacillus subtilis and modified to generate several vectors for molecular cloning purposes. In addition to having resistance to many antibiotics itself, at least one strain of C. xerosis also appears capable of producing antimicrobial compounds. These can inhibit bacteria and fungi, but the strength of antimicrobial activity by this strain depends on the carbon sources available. Also, a petroleum ether extract from C. xerosis was found to decrease the growth rate of tumors in mice, increasing their lifespan while being nontoxic to healthy mice. A study in 1967 confirmed the ability of several strains of C. xerosis to form single-layer "clumps" of cells around gas bubbles when cultures of the bacteria are suspended in buffer solutions at low temperatures with vigorous stirring. This property was attributed to cell surface proteins.
=== Nanorecording === In a nanorecording application, a certain rotaxane is deposited as a Langmuir–Blodgett film on ITO-coated glass. When a positive voltage is applied with the tip of a scanning tunneling microscope probe, the rotaxane rings in the tip area switch to a different part of the dumbbell and the resulting new conformation makes the molecules stick out 0.3 nanometer from the surface. This height difference is sufficient for a memory dot. It is not yet known how to erase such a nanorecording film.
Sources: en.wikipedia.org
Floyd Landis was the initial winner of the 2006 Tour de France. But a urine sample taken from Landis immediately after his Stage 17 win has twice tested positive for banned synthetic testosterone as well as a ratio of testosterone to epitestosterone nearly three times the limit allowed by World Anti-Doping Agency rules. The International Cycling Union stripped him of his 2006 Tour de France title. Second place finisher Óscar Pereiro was officially declared the winner.
Although genes were known to exist on chromosomes, chromosomes are composed of both protein and DNA, and scientists did not know which of the two was responsible for inheritance. In 1928, Frederick Griffith discovered the phenomenon of transformation: dead bacteria could transfer genetic material to "transform" other still-living bacteria. Sixteen years later, in 1944, the Avery–MacLeod–McCarty experiment identified DNA as the molecule responsible for transformation. The role of the nucleus as the repository of genetic information in eukaryotes had been established by Hämmerling in 1943 in his work on the single celled alga Acetabularia. The Hershey–Chase experiment in 1952 confirmed that DNA (rather than protein) is the genetic material of the viruses that infect bacteria, providing further evidence that DNA is the molecule responsible for inheritance. James Watson and Francis Crick determined the structure of DNA in 1953, using the X-ray crystallography work of Rosalind Franklin and Maurice Wilkins that indicated DNA has a helical structure (i.e., shaped like a corkscrew). Their double-helix model had two strands of DNA with the nucleotides pointing inward, each matching a complementary nucleotide on the other strand to form what look like rungs on a twisted ladder. This structure showed that genetic information exists in the sequence of nucleotides on each strand of DNA. The structure also suggested a simple method for replication: if the strands are separated, new partner strands can be reconstructed for each based on the sequence of the old strand.
The Instituto Universitario de Restauración del Patrimonio (the IRP) of the Polytechnic University of Valencia is a public Spanish institution dedicated to promoting heritage conservation research and practice.
== Side effects == Adverse events are generally caused by incorrect dosing. Long-term suppression of TSH values below normal values frequently causes cardiac side effects and contributes to decreases in bone mineral density (low TSH levels are also well known to contribute to osteoporosis). Too high a dose of levothyroxine causes hyperthyroidism. Overdose can result in heart palpitations, abdominal pain, nausea, anxiety, confusion, agitation, insomnia, weight loss, and increased appetite. Acute massive overdose may be life-threatening; treatment should be symptomatic and supportive. Massive overdose can be associated with increased sympathetic activity, thus may require treatment with beta blockers. The effects of overdosing appear 6 hours to 11 days after ingestion.
US international involvement in drug control rests on the premise that assisting foreign governments in their anti-drug efforts reduces drug supply within the US. Scholars have claimed that the war on drugs, a metaphorical war, is propaganda cloaking an extension of earlier military or paramilitary operations. Others have argued that large amounts of anti-drug foreign aid money, training, and equipment actually goes to fighting leftist insurgencies and is often provided to groups who themselves are involved in large-scale narco-trafficking, such as corrupt members of the Colombian military.
Sources: en.wikipedia.org
It is the copper complex of the tripeptide glycyl-L-histidyl-lysine. The metal ion is held by the histidine imidazole group and the peptide N-terminus. Most research on it concerns skin and wound models.
The tripeptide was first isolated from human plasma and has also been reported in saliva and urine. Plasma levels appear to decline with age in some small studies. Those observations rest on limited sample sizes.
It is not authorized as a systemic medicine in most countries. Cosmetic preparations list it as an ingredient rather than an active pharmaceutical substance. Legal status therefore differs by jurisdiction.
Identification usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. The copper content can be measured separately by inductively coupled plasma mass spectrometry or atomic absorption spectroscopy. The combination helps distinguish the intact complex from free peptide or free copper.